The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity

Vaccine

Volumn 25, Issue 42, 2007, Pages 7322-7330

  Park, Mi Young ^a   Kim, Chang Hyun ^a   Sohn, Hyun Jung ^a   Oh, Seong Taek ^b   Kim, Sung Guh ^c   Kim, Tai Gyu ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Boryung Pharm Co Ltd   (South Korea)

Author keywords

Adoptive T cell transfer; Combined immunotherapy; Dendritic cell (DC) vaccine

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY, ADOPTIVE; KINETICS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 34748846921     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.037     Document Type: Article

References (32)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
2. Pulendran B., Palucka K., and Banchereau J. Sensing pathogens and tuning immune responses. Science 293 5528 (2001) 253-256
3. Steinman R.M., and Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109 12 (2002) 1519-1526
4. Chang A.E., Redman B.G., Whitfield J.R., Nickoloff B.J., Braun T.M., Lee P.P., et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8 4 (2002) 1021-1032
5. Papewalis C., Fassnacht M., Willenberg H.S., Domberg J., Fenk R., Rohr U.P., et al. Dendritic cells as potential adjuvant for immunotherapy in adenocortical carcinoma. Clin Endocrinol 65 (2006) 215-222
6. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 10 5 (2004) 475-480
7. Comito M.A., Sun Q., and Lucas K.G. Immunotherapy for Epstein-Barr virus-associated tumors. Leuk Lymphoma 45 10 (2004) 1981-1987
8. Baxevanis C.N., Sotiriadou N.N., Gritzapis A.D., Sotiropoulou P.A., Perez S.A., Cacoullos N.T., et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55 1 (2006) 85-95
9. Straathof K.C., Bollard C.M., Popat U., Huls M.H., Lopez T., Morriss M.C., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105 5 (2005) 1898-1904
10. Hoffman D.M., Gitlitz B.J., Belldegrun A., and Figlin R.A. Adoptive cellular therapy. Semin Oncol 27 2 (2000) 221-233
11. Sauer M.G., Ericson M.E., Weigel B.J., Herron M.J., Panoskaltsis-Mortari A., Kren B.T., et al. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res 64 11 (2004) 3914-3921
12. Robbins P.F., Kantor J.A., Salgaller M., Hand P.H., Fernsten P.D., and Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51 14 (1991) 3657-3662
13. Inaba K., Turley S., Yamaide F., Iyoda T., Mahnke K., Inaba M., et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188 11 (1998) 2163-2173
14. Gunzer M., Weishaupt C., Planelles L., and Grabbe S. Two-step negative enrichment of CD4+ and CD8+ T cells from murine spleen via nylon wool adherence and an optimized antibody cocktail. J Immunol Methods 258 1-2 (2001) 55-63
15. Parish C.R. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol 81 2 (2003) 106-113
16. Van den Eynde B.J., and van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 9 5 (1997) 684-693
17. Ludewig B., Bonilla W.V., Dumrese T., Odermatt B., Zinkernagel R.M., and Hengartner H. Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur J Immunol 31 6 (2001) 1772-1779
18. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186 12 (1997) 2075-2080
19. Kim J.H., Chen J., Majumder N., Lin H., Falo Jr. L.D., and You Z. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity. Gene Ther 12 20 (2005) 1517-1525
20. MartIn-Fontecha A., Sebastiani S., Hopken U.E., Uguccioni M., Lipp M., Lanzavecchia A., et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198 4 (2003) 615-621
21. Bai X.F., Gao J.X., Liu J., Wen J., Zheng P., and Liu Y. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res 61 18 (2001) 6860-6867
22. Roychowdhury S., May Jr. K.F., Tzou K.S., Lin T., Bhatt D., Freud A.G., et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 64 21 (2004) 8062-8067
23. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3 9 (2003) 666-675
24. Marks-Konczalik J., Dubois S., Losi J.M., Sabzevari H., Yamada N., Feigenbaum L., et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 97 21 (2000) 11445-11450
25. Asada H., Kishida T., Hirai H., Shin-Ya M., Imanishi J., Takeuchi M., et al. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Cancer Lett 240 1 (2006) 83-93
26. Eggert A.A., Schreurs M.W., Boerman O.C., Oyen W.J., de Boer A.J., Punt C.J., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59 14 (1999) 3340-3345
27. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., and Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59 1 (1999) 56-58
28. Ali S., Ahmad M., Lynam J., Rees R.C., and Brown N. Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation. Int J Cancer 110 2 (2004) 239-244
29. Kim C.H., Johnston B., and Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+) V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100 1 (2002) 11-16
30. Weninger W., Manjunath N., and von Andrian U.H. Migration and differentiation of CD8+ T cells. Immunol Rev 186 1 (2002) 221-233
31. Lou Y., Wang G., Lizee G., Kim G.J., Finkelstein S.E., Feng C., et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64 18 (2004) 6783-6790
32. Katano M., Morisaki T., Koga K., Nakamura M., Onishi H., Matsumoto K., et al. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res 25 6A (2005) 3771-3776